The Anusandhan National Research Foundation (ANRF), which is backed by the Gates Foundation, leads efforts to enhance India’s research and innovation system. Their so-called goal is to promote health, science, and technology, and ANRF encourages teamwork among schools, the government, and businesses. The foundation focuses on creating solutions that are scalable, affordable, and have a positive impact on public welfare. It is assumed that by funding research and medical technologies, ANRF plays a part in India’s bigger dream of fair and accessible healthcare, tackling both local and worldwide issues through programs driven by innovation.
The Anusandhan National Research Foundation (ANRF), established in India to bolster the nation’s research and development capabilities, has faced significant criticism regarding its funding practices since its inception. These criticisms primarily revolve around its reliance on private funding, lack of transparency, potential for political influence, and centralisation of funding mechanisms.
Over-reliance on Private Funding and Corporate Influence
A major point of contention is the ANRF’s ambitious funding model, which projects that 72% of its Rs 50,000 crore budget over five years will be sourced from the private sector, philanthropists, and non-governmental entities. This leaves a comparatively smaller government contribution of Rs 14,000 crore over the same period. Critics, such as Dr. Dinesh Abrol from the All India Peoples Science Network (AIPSN), argue that this heavy dependence on corporate contributions places scientific endeavors at the “whims of corporate interests”. There are concerns that this model could skew research priorities towards projects promising immediate profits or “silver bullet” solutions favored by funders, potentially undermining academic freedom and neglecting basic or curiosity-driven research that may not have immediate commercial applications. The current reality has fallen short of these promises, with neither the government nor the private sector delivering the committed funds, casting doubt on the feasibility of ANRF’s objectives.
Lack of Transparency and Accountability
The ANRF has been criticized for its lack of transparency regarding the sources and allocation of private funding. There is no clear public information about which private players or philanthropists have contributed, their names, or the amounts donated. This opacity raises concerns about potential hidden agendas, conflicts of interest, and whether contributors are profiting from their investments. Dr. Abrol highlights that the shift from a transparent public funding mechanism to one “shrouded in uncertainty” introduces unpredictability and potential bias, undermining trust in the system. Furthermore, critics argue there is a lack of government accountability for this funding system, with concerns about sanctioned money not reaching its intended beneficiaries.
Potential for Political Influence
Many scientists and researchers fear that the new funding model will allow political affiliations and the ruling party to influence research funding decisions. There are apprehensions that project proposals might be rejected not on merit but on political grounds, depending on the source of the proposal or the government in power in a particular state. Prof. Dhrubajyoti Mukherjee, President of the Breakthrough Science Society, expressed worry that such centralization could lead to political interference and that corporate funders would play a significant role, which is not conducive to healthy scientific research.
Centralisation and Restricted Opportunities
The ANRF’s mandate to centralize scientific research funding in India has been viewed as a double-edged sword. Prof. Soumitro Banerjee from IISER Kolkata points out that previously, researchers had multiple funding agencies to approach, offering flexibility. However, with the ANRF becoming a singular funding agency, this flexibility is eliminated, potentially restricting opportunities and stifling innovation and research. This move from a decentralized to a centralized system is seen as a significant shift that could limit avenues for researchers.
Inadequate Representation and Bureaucracy
The composition of the ANRF’s Governing Board and Executive Council has also drawn criticism for its lack of diverse representation. Notably, there is a significant absence of members from Central or State universities and colleges, despite the ANRF’s aim to strengthen research infrastructure in these institutions. Critics argue that the committees resemble typical government committees, lacking representation from Indian industry, entrepreneurs, or eminent academics from universities, which are crucial for understanding ground-level bottlenecks and fostering industry-academia collaboration. The existing bureaucracy within the Indian university system is also cited as a deterrent for industry partners, making collaborations cumbersome and slow, despite the ANRF’s intent to facilitate such partnerships.
Underfunding of R&D and Focus Shift
India’s overall expenditure on Research and Development (R&D) remains low globally, at around 0.65% of its GDP in 2022, a decline from previous years. Critics argue that the ANRF’s proposed government contribution is insufficient to address this systemic underfunding. While the ANRF aims to support basic research and prototype development, its industry-centric orientation and emphasis on “marketable” research raise concerns about a potential shift away from fundamental or curiosity-driven science. This could lead to the commodification of research outcomes and neglect critical sectors like social sciences, economics, and climate change, which may not offer immediate commercial returns.
In summary, while the ANRF was established with the noble goal of enhancing India’s R&D capabilities, its implementation and proposed funding mechanisms have generated substantial concerns within the scientific community regarding its long-term effectiveness and potential impact on the integrity and direction of Indian research.
Flaws in the MAHA MedTech Mission:
The Mission for Advancement in High-Impact Areas (MAHA) – MedTech Mission, launched on October 25, 2025, by the Anusandhan National Research Foundation (ANRF) in partnership with the Indian Council of Medical Research (ICMR) and the Bill & Melinda Gates Foundation:
- Funding: Milestone-linked grants of ₹5-25 crore per project (up to ₹50 crore in exceptional cases), totaling around ₹750 crore over the mission period. Open to academia, R&D institutions, hospitals, startups, MSMEs, and MedTech firms, it aims to cut India’s 80-85% import dependence on medical devices and address priorities like TB, cancer, and neonatal care.
- Focus Areas: Innovative devices (e.g., diagnostic imaging, robotics, AI/ML platforms, implants, minimally invasive tools) and in-vitro diagnostics, with emphasis on adaptation for low-resource settings.
- Support Ecosystem: Beyond funding, it offers Patent Mitra (IP protection), MedTech Mitra (regulatory guidance), a national Clinical Trial Network, and industry mentorship to foster industry-academia collaborations.
- Objectives: Enhance self-reliance (Atmanirbhar Bharat), improve healthcare equity, and position India as a global MedTech leader.
The mission aligns with R&D under the ANRF Act, 2023, and builds on India’s growing MedTech market (projected to reach $50 billion by 2030).
However, as a nascent program (concept notes due by November 7, 2025), it has faced widespread scrutiny.
That said, potential flaws can be identified from the mission’s structure, historical parallels in similar initiatives (e.g., Gates-backed health projects), and broader R&D challenges in India. These are largely prospective risks rather than proven issues, drawn from policy documents, expert analyses of analogous programs, and patterns in India’s innovation ecosystem. Below, I outline key flaws, their implications, and evidence-based substantiation.
Key Flaws and Risks
| Flaw | Description | Potential Implications | Basis/Evidence |
|---|---|---|---|
| Over-Reliance on Foreign Philanthropy and Agenda Influence | The Gates Foundation’s prominent role raises concerns about donor-driven priorities (e.g., global health agendas like population health metrics) potentially overshadowing local needs, such as region-specific diseases or affordability for rural India. Past Gates projects in India (e.g., Avahan HIV initiative) have been accused of “philanthropic colonialism” by prioritizing scalable, exportable models over grassroots adaptations. | Could lead to biased tech development (e.g., favoring urban diagnostics over rural preventive tools), eroding policy sovereignty and creating dependency on external funding cycles. | Inferred from critiques of Gates’ India portfolio; no direct MAHA evidence yet, but echoes ANRF Act debates on private/foreign funding. Program docs emphasize “Gates collaboration” without safeguards for Indian veto rights. |
| Cost-Sharing Burdens on Under-Resourced Entities | Private participants (startups/MSMEs) must contribute to project costs from their own resources, amid India’s tight credit environment for deep tech (success rates ~10-15%). This excludes smaller innovators, favoring established firms. | Exacerbates inequality in the MedTech ecosystem; limits diversity of ideas and favors corporate players, contradicting the mission’s inclusivity goals. | Explicit in CFP guidelines: “Private entities must contribute to project costs.” Aligns with low private GERD (36% of total R&D), per Economic Survey 2025. |
| Bureaucratic Hurdles and Milestone Rigidity | Funding is milestone-linked with ANRF/ICMR oversight, including audits and approvals, which could delay agile R&D in a fast-evolving field like AI-driven diagnostics. India’s “Ease of Doing Research” scores low due to such red tape. | Stifles innovation velocity; high dropout risk for time-sensitive projects, mirroring delays in schemes like IMPRINT. | CFP outlines “rigorous compliance” and potential “additional scrutiny.” NITI Aayog’s 2025 review flags similar issues in R&D funding. |
| Insufficient Emphasis on Basic vs. Applied Research | Prioritizes “established proof-of-concept” projects for commercialization, potentially underfunding foundational work in emerging areas like quantum-enabled imaging or biotech. This mirrors ANRF’s broader private-funding tilt (70% target from non-public sources). | Hinders long-term breakthroughs; risks a “valley of death” where basic research stalls without translation support. | Mission FAQ: Focus on “innovative/affordable products to commercialization.” Experts note India’s R&D skew toward applied tech (e.g., 54% public funds to defense/space). |
| Equity and Scalability Gaps | While targeting low-resource settings, the urban-centric partnerships (e.g., with IITs/MSMEs) may overlook rural distribution challenges. No explicit mechanisms for regional equity (e.g., Northeast allocation). | Urban-rural health divide widens; innovations may remain inaccessible, failing SDG-aligned goals. | Program scope: “Adaptation for low-resource settings” mentioned but not quantified. Historical Gates pilots (e.g., sanitation) critiqued for elite focus. |
| Transparency and Accountability Shortfalls | Limited details on fund allocation criteria, board composition, or post-grant monitoring. Preparatory CFP is “non-binding,” raising questions on evaluation fairness. | Risk of favoritism or inefficiency; erodes trust, especially post-ANRF Act concerns over governance opacity. | CFP: “Some technologies will be further evaluated” without full criteria. PRS India analyses of similar bills highlight similar gaps. |
The Bill & Melinda Gates Foundation faces backlash for perceived foreign influence, corporate ties, and ethical concerns:
- Funding Cuts/Policy Shifts: In 2017, India reduced ITSU funding amid sovereignty debates, viewing it as over-reliance on external aid.
- GMOs and Agriculture: Critics (e.g., activists like Vandana Shiva) link BMGF-backed seeds to farmer debt/suicides, calling it “corporate capture.” Voices from Jawaharlal Nehru University or public health forums, echoing the ANRF Act concerns over the privatization of research.
- Vaccines/Population Control: Accusations of promoting untested shots or depopulation agendas; 2019 Goalkeepers Award to PM Modi drew global protests from academics/human rights groups over Kashmir policies.
- Surveillance Fears: Gates’ praise for Aadhaar as a “command center” raises privacy alarms, seen as enabling mass tracking.
- Public Sentiment: On X (as of Oct 2025), posts criticize “dangerous projects” like GMOs, bio-mosquitoes, and foreign interference, with calls to expel BMGF/WHO. Examples include Kenyan court parallels and anti-vax narratives. Nationalist voices urge self-reliance over “philanthropic colonialism.”
Potential Drawbacks
However, based on structural elements of the program and historical patterns in similar Gates Foundation-backed health initiatives in India (e.g., vaccine programs or agricultural tech), potential drawbacks can be inferred from expert commentary on comparable efforts. These include risks of foreign influence, funding dependencies, and implementation hurdles. Widespread backlash has emerged, and watchdogs may scrutinize it in the coming months.
| Drawback | Description | Potential Impact | Basis/Context |
|---|---|---|---|
| Heavy Reliance on Foreign Philanthropy | Gates Foundation’s involvement could lead to agenda-setting influenced by global priorities (e.g., population control or specific disease focus), potentially sidelining purely indigenous needs. Historical Gates projects in India have faced accusations of “philanthropic colonialism.” | May prioritize donor-aligned tech over local innovations, risking sovereignty in health policy. | Inferred from past critiques of Gates’ role in India’s health space; no direct MAHA-specific evidence yet. |
| Private Sector Cost-Sharing Burdens | Private entities (startups/MSMEs) must contribute to project costs from own resources, which could exclude smaller players amid India’s credit crunch for deep tech. | Widens inequality; favors established firms, limiting diversity in innovation. | Explicit in funding terms; echoes R&D challenges like low private GERD contribution (~36%). |
| Bureaucratic and Milestone Risks | Milestone-based funding requires rigorous compliance, with potential delays in approvals or audits under ANRF/ICMR oversight. | Stifles agile innovation; high failure rate for startups (India’s deep-tech success rate ~10-15%). | Similar to ANRF’s broader critiques; preparatory CFP notes potential for additional scrutiny. |
| Limited Scope for Basic Research | Emphasis on commercialization and high-impact imports adaptation may underfund foundational R&D, mirroring ANRF’s private-funding tilt. | Hinders long-term breakthroughs; focuses on market-ready tech over exploratory work. | Aligned with ANRF Act concerns; mission prioritizes “established proof-of-concept” projects. |
| Equity and Accessibility Gaps | While aiming for affordability, scaling to rural/low-resource areas could falter without robust distribution mechanisms. | Benefits urban hubs more; exacerbates urban-rural health divides. | Potential from mission’s urban-centric partnerships; historical Gates initiatives critiqued for elite focus. |
Ref:
- ANRF: India’s Research Funding at Risk. [ https://theprobe.in/science-technology/anrf-indias-research-funding-at-risk-4754490 ]
- The ANRF plan has got off on the wrong foot. [https://www.thehindu.com/opinion/op-ed/the-anrf-plan-has-got-off-on-the-wrong-foot/article68378731.ece ]
- Funding the Future: How the ANRF’s Skewed Approach has Reignited the Debate on the Corporatisation of Research. [ https://spicyip.com/2024/10/funding-the-future-how-the-anrfs-skewed-approach-has-reignited-the-debate-on-the-corporatisation-of-research.html ]
- Budget 2024-25: Operationalisation of ANRF may be too little, too late. [https://www.downtoearth.org.in/science-technology/budget-2024-25-operationalisation-of-anrf-may-be-too-little-too-late ]
- The Anusandhan National Research Foundation (ANRF), the new central agency to govern science in India, officially rolled out this month with the announcement of an Executive Council and Governing Board. [ https://www.nature.com/articles/d44151-024-00105-8 ]
- Better Reviews, Fairer Funding? Reflections on ANRF NPDF 2025. [ https://www.linkedin.com/posts/aaftaab_better-reviews-fairer-funding-reflections-activity-7377668724046053376-Ifd9 ]
- ANRF: India’s Research Funding at Risk. [ https://www.teamblind.com/post/anrf-indias-research-funding-at-risk-tzruagjv ]